Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
175 Results for "
PTP1B
" in MedChemExpress (MCE) Product Catalog:
Products (175)
175 Results for "PTP1B" in MCE Product Catalog:
Cat. No.: HY-N13813
CAS No.: 143051-74-5
Target:
Cat. No.: HY-124896
CAS No.: 97126-57-3
Synonyms: 6-Geranylnaringenin; Mimulone
Target:
Cat. No.: HY-138964
CAS No.: 1187396-28-6
Target:
Research Areas:
TC-PTP-IN-1 (compound 8) is a potent TC-PTP inhibitor with an IC50 value of 9.2 nM, Ki values of 4.3, 34 nM for TC-PTP, PTP1B, respectively. TC-PTP-IN-1 increases the protein expression of pSre416 [1]. TC-PTP-IN-1 (compound 3) is the TC-PTP Ligand of TP1L (HY-160151) .
Cat. No.: HY-155558
CAS No.: 3028076-11-8
Target:
Research Areas:
MptpB-IN-2 (compound 20) is a selective mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with IC50s of 0.64 μM, 4.06 μM and 4.14 μM for MptpB, MptpA and PTP1B, respectively. MptpB-IN-2 shows weak antituberculosis activity with a MIC of 64.9 μM for Mtb H37Rv [1].
Cat. No.: HY-W002314
CAS No.: 2491-38-5
Research Areas:
2-Bromo-4'-hydroxyacetophenone is a PTP1B inhibitor with a Ki value of 42 μM. 2-Bromo-4'-hydroxyacetophenone is also an intermediate. 2-Bromo-4'-hydroxyacetophenone can be used in the synthesis of LXRα/β antagonists. 2-Bromo-4'-hydroxyacetophenone can be used in research on hematological diseases [1] .
Cat. No.: HY-N1117
CAS No.: 139101-67-0
Target:
Target:
Research Areas:
JUN-1111 is an irreversible and selective Cdc25 phosphatase inhibitor with IC50 values of 0.38, 1.8, 0.66, 28, 37 µM for Cdc25A, Cdc25B, Cdc25C, VHR, PTP1B, respectively. JUN-1111 induces cell cycle arrest at G1 and G2/M phases. JUN-1111 decreases the expression of phosphoCdk1 [1] .
Cat. No.: HY-148922
CAS No.: 2213365-56-9
Target:
Research Areas:
PPARα/γ agonist 2 is an orally active PPARα full agonist and PPARγ partial agonist. PPARα/γ agonist 2 activates PPARα and PPARγ with EC50 values of 0.95 μM and 0.91 μM respectively. PPARα/γ agonist 2 is also a PTP1B inhibitor. PPARα/γ agonist 2 is an anti-diabetic agent [1].
Cat. No.: HY-N1941
CAS No.: 17290-70-9
Cat. No.: HY-149760
CAS No.: 3032975-48-4
Target:
Research Areas:
PVD-06 is a selective PROTAC PTPN2 degrader with a DC50 of 217 nM (selectivity index >60-fold over PTP1B). PVD-06 induces PTPN2 degradation via a VHL-, ubiquitin, and proteasome-dependent pathway. PVD-06 can promote T cell activation and amplify IFN-γ-mediated anticancer activity. PVD-06 can be used to further investigate PTPN2 in diseases such as leukemia and melanoma [1].
Cat. No.: HY-179380
CAS No.: 3093350-44-5
Target:
Research Areas:
PTPN2-IN-2 is a potent and orally active PTPN2 inhibitor (IC50 = 7.05 nM) that enhances the IFN-γ signaling pathway. PTPN2-IN-2 inhibits PTP1B with an IC50 of 9.88 nM. PTPN2-IN-2 inhibits tumor growth, promotes the activation and infiltration of tumor immune cells in a B16-OVA mouse model. PTPN2-IN-2 can be used for the research of melanoma [1].
Cat. No.: HY-N2217
CAS No.: 20137-37-5
Cat. No.: HY-178295
CAS No.: 956442-05-0
Target:
Research Areas:
VHR-IN-5 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 78 nM. VHR-IN-5 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.78 μM), CD45 (IC50 = 0.61 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 1.8 μM), and HePTP (IC50 = 1.5 μM). VHR-IN-5 inhibits the proliferation of HeLa cells. VHR-IN-5 can be used for the research of cervical cancer [1].
Cat. No.: HY-178296
CAS No.: 1146616-16-1
Target:
Research Areas:
VHR-IN-6 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 74 nM. VHR-IN-6 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.52 μM), CD45 (IC50 = 0.50 μM), Cdc25A (IC50 = 2.8 μM), PTP1B (IC50 = 0.42 μM), and HePTP (IC50 = 0.87 μM). VHR-IN-6 inhibits the proliferation of HeLa cells. VHR-IN-6 can be used for the research of cervical cancer [1].
Cat. No.: HY-178297
CAS No.: 1146616-17-2
Target:
Research Areas:
VHR-IN-7 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 71 nM. VHR-IN-7 shows very weaker inhibitory activity against MKP-1 (IC50 = 0.47 μM), CD45 (IC50 = 0.3 μM), Cdc25A (IC50 = 3.4 μM), PTP1B (IC50 = 0.59 μM), and HePTP (IC50 = 1.2 μM). VHR-IN-7 inhibits the proliferation of HeLa cells. VHR-IN-7 can be used for the research of cervical cancer [1].
Cat. No.: HY-178301
CAS No.: 1146616-18-3
Target:
Research Areas:
VHR-IN-9 is a selective vaccinia H1-related (VHR) phosphatase inhibitor with an IC50 of 270 nM. VHR-IN-9 shows very weaker inhibitory activity against MKP-1 (IC50 = 2.8 μM), CD45 (IC50 = 1.8 μM), Cdc25A (IC50 = > 10 μM), PTP1B (IC50 = 2.2 μM), and HePTP (IC50 = 2.4 μM). VHR-IN-9 inhibits the proliferation of HeLa cells. VHR-IN-9 can be used for the research of cervical cancer [1].
Cat. No.: HY-N19818
CAS No.: 2088505-67-1
Cat. No.: HY-173217
Target:
Research Areas:
PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia [1].
Cat. No.: HY-183573
Research Areas:
PTPRO-IN-1 is a selective, orally active PTPRO inhibitor with an IC50 of 0.16 μM. PTPRO-IN-1 exhibits IC50 values of 2.4 μM, 2.33 μM and 2.13 μM against PTPN22, PTP1B and PTPRT, respectively, and shows almost no inhibitory activity against STEP/SSH2. PTPRO-IN-1 inhibits the TLR4/NF-κB signaling pathway in macrophages, ameliorates colonic pathological conditions and suppresses the secretion of pro-inflammatory cytokines by T cells. PTPRO-IN-1 can be used for the research of inflammatory bowel disease [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
